{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:02:21Z","timestamp":1740135741906,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several studies have investigated the association between P2Y12 reaction unit (PRU) value and major adverse cardiovascular events (MACEs) in patients with ischemic heart disease, but there is no well-established consensus on the utility of PRU value. Furthermore, the optimal PRU cut-off value varied with studies. One reason may be that the endpoints and observation periods differed, depending on the study. This study aimed to investigate the optimal cut-off and predictive ability of the PRU value for predicting cardiovascular events, while considering different endpoints and observation periods. We surveyed a total of 338 patients receiving P2Y12 inhibitors and measured PRU during cardiac catheterization. Using time-dependent receiver operating characteristic analysis, we evaluated the cut-off and area under curve (AUC) of the PRU value for two MACEs (MACE \u2460: composite of death, myocardial infarction, stent thrombosis, and cerebral infarction; MACE \u2461: composite of MACE \u2460 and target vessel revascularization) at 6, 12, 24 and 36\u00a0months after cardiac catheterization. MACE \u2460 occurred in 18 cases and MACE \u2461 in 32 cases. The PRU cut-off values at 6, 12, 24, and 36\u00a0months were 257, 238, 217, and 216, respectively, for MACE \u2460 and 250, 238, 209, and 204, respectively, for MACE \u2461. The AUCs at 6, 12, 24, and 36\u00a0months were 0.753, 0.832, 0.718, and 0.717, respectively, for MACE \u2460 and 0.724, 0.722, 0.664, and 0.682, respectively, for MACE \u2461. The optimal cut-off and predictive ability of PRU values for cardiovascular events varied depending on different endpoints and duration of the observation periods. A relatively high PRU value is effective for short-term event suppression, but a low value is required for long-term event suppression.<\/jats:p>","DOI":"10.1007\/s00380-023-02279-0","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T15:02:02Z","timestamp":1686841322000},"page":"1218-1227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Time-dependent changes in P2Y12 reaction unit values for predicting the different types of cardiovascular events in patients with ischemic heart disease"],"prefix":"10.1007","volume":"38","author":[{"given":"Takatoku","family":"Aizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0823-4664","authenticated-orcid":false,"given":"Yasunori","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Nagoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Minai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"12","key":"2279_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","volume":"56","author":"L Bonello","year":"2010","unstructured":"Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA, Working Group on High On-Treatment Platelet R (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56(12):919\u2013933","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2279_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2010.03.048","volume":"56","author":"D Sibbing","year":"2010","unstructured":"Sibbing D, Steinhubl SR, Schulz S, Schomig A, Kastrati A (2010) Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 56(4):317\u2013318","journal-title":"J Am Coll Cardiol"},{"key":"2279_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1160\/TH07-09-0575","volume":"99","author":"JA Jakubowski","year":"2008","unstructured":"Jakubowski JA (2008) The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 99:409\u2013415","journal-title":"Thromb Haemost"},{"issue":"3","key":"2279_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.thromres.2006.01.019","volume":"119","author":"A Malinin","year":"2007","unstructured":"Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V (2007) Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 119(3):277\u2013284","journal-title":"Thromb Res"},{"issue":"3","key":"2279_CR5","doi-asserted-by":"publisher","first-page":"562 e561","DOI":"10.1016\/j.ahj.2008.11.021","volume":"157","author":"C Varenhorst","year":"2009","unstructured":"Varenhorst C, James S, Erlinge D, Braun OO, Brandt JT, Winters KJ, Jakubowski JA, Olofsson S, Wallentin L, Siegbahn A (2009) Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 157(3):562 e561-569","journal-title":"Am Heart J"},{"issue":"19","key":"2279_CR6","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","volume":"58","author":"SS Brar","year":"2011","unstructured":"Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G (2011) Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58(19):1945\u20131954","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2279_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.2010.181","volume":"303","author":"NJ Breet","year":"2010","unstructured":"Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303(8):754\u2013762","journal-title":"JAMA"},{"issue":"8","key":"2279_CR8","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1080\/09537104.2018.1562172","volume":"30","author":"SN Lee","year":"2019","unstructured":"Lee SN, Moon D, Sung MK, Moon KW, Yoo KD (2019) Impact of platelet reactivity on long-term prognosis in Korean patients receiving percutaneous coronary intervention. Platelets 30(8):1030\u20131035","journal-title":"Platelets"},{"issue":"2","key":"2279_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","volume":"119","author":"R Marcucci","year":"2009","unstructured":"Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF (2009) Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119(2):237\u2013242","journal-title":"Circulation"},{"issue":"6","key":"2279_CR10","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1007\/s00380-021-02003-w","volume":"37","author":"Y Matsumaru","year":"2022","unstructured":"Matsumaru Y, Kitazono T, Kadota K, Nakao K, Nakagawa Y, Shite J, Yokoi H, Kozuma K, Tanabe K, Akasaka T, Shinke T, Ueno T, Hirayama A, Uemura S, Kuroda T, Takita A, Harada A, Iijima R, Murakami Y, Saito S, Nakamura M (2022) Relationship between platelet aggregation and stroke risk after percutaneous coronary intervention: a PENDULUM analysis. Heart Vessels 37(6):942\u2013953","journal-title":"Heart Vessels"},{"issue":"10","key":"2279_CR11","doi-asserted-by":"publisher","first-page":"e015439","DOI":"10.1161\/JAHA.119.015439","volume":"9","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Kadota K, Takahashi A, Kanda J, Anzai H, Ishii Y, Shibata Y, Yasaka Y, Takamisawa I, Yamaguchi J, Takeda Y, Harada A, Motohashi T, Iijima R, Uemura S, Murakami Y, Investigators* PR (2020) Relationship between platelet reactivity and ischemic and bleeding events after percutaneous coronary intervention in East Asian patients: 1-year results of the PENDULUM registry. J Am Heart Assoc 9(10):e015439","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"2279_CR12","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jacc.2008.06.038","volume":"52","author":"G Patti","year":"2008","unstructured":"Patti G, Nusca A, Mangiacapra F, Gatto L, D\u2019Ambrosio A, Di Sciascio G (2008) Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 52(14):1128\u20131133","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2279_CR13","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","volume":"124","author":"MJ Price","year":"2011","unstructured":"Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124(10):1132\u20131137","journal-title":"Circulation"},{"issue":"11","key":"2279_CR14","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.amjcard.2007.01.023","volume":"99","author":"AN Buch","year":"2007","unstructured":"Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R (2007) Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 99(11):1518\u20131522","journal-title":"Am J Cardiol"},{"key":"2279_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:614\u2013623","journal-title":"Lancet"},{"issue":"2","key":"2279_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4244\/EIJV10I2A34","volume":"10","author":"V Legrand","year":"2014","unstructured":"Legrand V, Cuisset T, Chenu P, Vrolix M, Martinez C, Dens J, Gach O, Boland J, Claeys MJ, Magne J, Barbato E, Wijns W (2014) Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial. EuroIntervention 10(2):204\u2013211","journal-title":"EuroIntervention"},{"issue":"6","key":"2279_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.4070\/kcj.2012.42.6.382","volume":"42","author":"LH Yu","year":"2012","unstructured":"Yu LH, Kim MH, Zhang HZ, Park JS, Park TH, Kim YD, Cha KS, Han JY (2012) Impact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: platelet responsiveness and clinical outcome. Korean Circ J 42(6):382\u2013389","journal-title":"Korean Circ J"},{"issue":"2","key":"2279_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56(2):337\u2013344","journal-title":"Biometrics"},{"issue":"3","key":"2279_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","volume":"40","author":"K Thygesen","year":"2019","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Mickley H, Crea F, Van de Werf F, Bucciarelli-Ducci C, Katus HA, Pinto FJ, Antman EM, Hamm CW, De Caterina R, Januzzi JL, Apple FS, Alonso Garcia MA, Underwood SR, Canty JM, Lyon AR, Devereaux PJ, Zamorano JL, Lindahl B, Weintraub WS, Newby LK, Virmani R, Vranckx P, Cutlip D, Gibbons RJ, Smith SC, Atar D, Luepker RV, Robertson RM, Bonow RO, Steg PG, O\u2019Gara PT, Fox KAA, Hasdai D, Aboyans V, Achenbach S, Agewall S, Alexander T, Avezum A, Barbato E, Bassand J-P, Bates E, Bittl JA, Breithardt G, Bueno H, Bugiardini R, Cohen MG, Dangas G, de Lemos JA, Delgado V, Filippatos G, Fry E, Granger CB, Halvorsen S, Hlatky MA, Ibanez B, James S, Kastrati A, Leclercq C, Mahaffey KW, Mehta L, M\u00fcller C, Patrono C, Piepoli MF, Pi\u00f1eiro D, Roffi M, Rubboli A, Sharma S, Simpson IA, Tendera M, Valgimigli M, van der Wal AC, Windecker S, Chettibi M, Hayrapetyan H, Roithinger FX, Aliyev F, Sujayeva V, Claeys MJ, Smaji\u0107 E, Kala P, Iversen KK, El Hefny E, Marandi T, Porela P, Antov S, Gilard M, Blankenberg S, Davlouros P, Gudnason T, Alcalai R, Colivicchi F, Elezi S, Baitova G, Zakke I, Gustiene O, Beissel J, Dingli P, Grosu A, Damman P, Julieb\u00f8 V, Legutko J, Morais J, Tatu-Chitoiu G, Yakovlev A, Zavatta M, Nedeljkovic M, Radsel P, Sionis A, Jemberg T, M\u00fcller C, Abid L, Abaci A, Parkhomenko A, Corbett S (2019) Fourth universal definition of myocardial infarction (2018). Eur Heart J 40(3):237\u2013269","journal-title":"Eur Heart J"},{"issue":"23","key":"2279_CR20","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123(23):2736\u20132747","journal-title":"Circulation"},{"issue":"3","key":"2279_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl 48(3):452\u2013458","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2279_CR22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jcmg.2011.12.019","volume":"5","author":"AP Chirumamilla","year":"2012","unstructured":"Chirumamilla AP, Maehara A, Mintz GS, Mehran R, Kanwal S, Weisz G, Hassanin A, Hakim D, Guo N, Baber U, Pyo R, Moses JW, Fahy M, Kovacic JC, Dangas GD (2012) High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging 5(5):540\u2013549","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"2279_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.atherosclerosis.2008.04.001","volume":"202","author":"AM Gori","year":"2009","unstructured":"Gori AM, Cesari F, Marcucci R, Giusti B, Paniccia R, Antonucci E, Gensini GF, Abbate R (2009) The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 202(1):255\u2013262","journal-title":"Atherosclerosis"},{"issue":"6","key":"2279_CR24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1160\/TH10-05-0266","volume":"104","author":"I Bernlochner","year":"2010","unstructured":"Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, Mehilli J, von Beckerath N, Sch\u00f6mig A, Kastrati A, Sibbing D (2010) Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 104(6):1193\u20131200","journal-title":"Thromb Haemost"},{"issue":"6","key":"2279_CR25","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s00380-023-02250-z","volume":"38","author":"Y Hori","year":"2023","unstructured":"Hori Y, Sakakura K, Jinnouchi H, Taniguchi Y, Tsukui T, Watanabe Y, Yamamoto K, Seguchi M, Wada H, Fujita H (2023) Association of peak C-reactive protein with long-term clinical outcomes in patients with ST-segment elevation myocardial infarction. Heart Vessels 38(6):764\u2013772","journal-title":"Heart Vessels"},{"issue":"24","key":"2279_CR26","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","volume":"62","author":"US Tantry","year":"2013","unstructured":"Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA, Working Group on On-Treatment Platelet R (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62(24):2261\u20132273","journal-title":"J Am Coll Cardiol"},{"key":"2279_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ahj.2017.02.003","volume":"187","author":"A Bagai","year":"2017","unstructured":"Bagai A, Peterson ED, McCoy LA, Effron MB, Zettler ME, Stone GW, Henry TD, Cohen DJ, Schulte PJ, Anstrom KJ, Wang TY (2017) Association of measured platelet reactivity with changes in P2Y(12) receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. Am Heart J 187:19\u201328","journal-title":"Am Heart J"},{"issue":"1","key":"2279_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.amjcard.2008.08.048","volume":"103","author":"L Bonello","year":"2009","unstructured":"Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, Giacomoni MP, Bonello R, Collet F, Rossi P, Barragan P, Dignat-George F, Paganelli F (2009) Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 103(1):5\u201310","journal-title":"Am J Cardiol"},{"issue":"14","key":"2279_CR29","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","volume":"51","author":"L Bonello","year":"2008","unstructured":"Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F (2008) Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51(14):1404\u20131411","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2279_CR30","doi-asserted-by":"publisher","first-page":"e005781","DOI":"10.1136\/bmjopen-2014-005781","volume":"4","author":"G Christ","year":"2014","unstructured":"Christ G, Siller-Matula JM, Francesconi M, Dechant C, Grohs K, Podczeck-Schweighofer A (2014) Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open 4(10):e005781","journal-title":"BMJ Open"},{"issue":"1","key":"2279_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11239-012-0684-z","volume":"34","author":"D Hazarbasanov","year":"2012","unstructured":"Hazarbasanov D, Velchev V, Finkov B, Postadjian A, Kostov E, Rifai N, Aradi D (2012) Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis 34(1):85\u201390","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"2279_CR32","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ijcard.2012.05.040","volume":"167","author":"JM Siller-Matula","year":"2013","unstructured":"Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeck-Schweighofer A, Christ G (2013) Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 167(5):2018\u20132023","journal-title":"Int J Cardiol"},{"issue":"4","key":"2279_CR33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.amjcard.2012.04.020","volume":"110","author":"JS Jang","year":"2012","unstructured":"Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Seol SH, Kim DI, Kim BH, Park YH, Je HG, Jeong YH, Lee SW (2012) Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol 110(4):502\u2013508","journal-title":"Am J Cardiol"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-023-02279-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-023-02279-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-023-02279-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T14:05:26Z","timestamp":1693317926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-023-02279-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2279"],"URL":"https:\/\/doi.org\/10.1007\/s00380-023-02279-0","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"type":"print","value":"0910-8327"},{"type":"electronic","value":"1615-2573"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takayuki Ogawa reports that there are no relevant conflicts of interest. Outside the submitted work, Takayuki Ogawa received personal fees from Terumo Co. and personal fees from Kaneka Co. Makoto Kawai has no conflict of interest and reports that there are no relevant conflicts of interest. Outside the submitted work, Makoto Kawai received scholarship donations from Daiichi Sankyo Co., Ltd. Michihiro Yoshimura reports that there are no relevant conflicts of interest. Outside the submitted work, Michihiro Yoshimura received lecture\u00a0fees from Mochida Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., Kowa Co., Ltd., and Astra Zeneca Plc., as well as scholarship donations from Teijin Pharma Ltd. and Shionogi & Co., Ltd. The other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}